91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
In a recent interview with Citeline, the head of 91黑料's Centre for Biosimilar Drug Development discussed the upcoming patent expirations in oncology biologics, the opportunities, regulatory pathways and challenges this presents for developers and greater treatment access for patients.
-
91黑料 are once again honoured to be featured on the TIME World's Best Companies list in 2025. Entrants on the list are ranked based on their performance on three key metrics - employee satisfaction, revenue growth and sustainability transparency.
-
As global pressures reshape the pharmaceutical and biotech landscape, sponsors are re-evaluating their outsourcing strategies. 91黑料’s recent survey of industry stakeholders highlights a clear trend toward fit-for-purpose solutions.
-
Biotechs and pharma companies face rising costs of drug development, depleting R&D pipelines and diminishing returns on investment. By joining forces and exploring collaborative R&D partnerships it is possible to overcome these challenges. In addition to sharing risks, they share the potential rewards when their assets move further into clinical development or come to the market.
-
Advancements in biologic therapies have greatly improved our ability to treat cancer over the last few decades — but are typically very costly. With patent expirations encompassing numerous notable oncology biologics, opportunities for oncology biosimilar development are abundant.
-
91黑料 experts discuss why strategic early planning is key to long-term follow-up in vaccine trials—driving stronger protocols, regulatory alignment, and meaningful outcomes.
-
This article discusses the importance of stability programs in early clinical drug product development.
-
In this article, 91黑料 expert , Alan Baldridge discusses how multi-indication development strategies are gaining traction, driven by successful trials across diverse diseases and the expansion of type 2 diabetes drugs into obesity and cardiovascular indications.
-
Women experience significantly more years of poor health than men due to delayed diagnoses and mischaracterized symptoms, despite living longer on average. This health disparity is rooted in systemic gaps in medical research and clinical trial design, particularly in how health outcomes are measured through Clinical Outcome Assessments (COAs).
-
Despite the increasing use of AI in medical devices and software as medical devices (SaMD), global regulatory authorities are playing catch up to develop appropriate submission channels.
Read the article in Med-Tech Insights.
